{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-018788","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2023-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.154212+00:00","generated_at":"2026-06-15T12:18:34.450384+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Enanta Q2 net loss widens to $37.7M; reports positive Phase 2 COVID-19 data, $200M royalty sale","bullets":["Net loss $37.7M ($1.79 loss/diluted share) vs $33.6M loss ($1.63) YoY; revenue $17.8M from HCV royalties.","Positive Phase 2 SPRINT data for EDP-235 (COVID-19): met primary endpoint; 400mg showed symptom improvement vs placebo.","Sold 54.5% of future MAVYRET royalties to OMERS for $200M upfront; cash runway extended into calendar 2026.","Cash and marketable securities $225.1M at March 31, 2023; plus remaining 45.5% royalty stream after cap.","Phase 1 data for RSV L-protein inhibitor EDP-323 expected in June; dual hMPV/RSV candidate selection in Q4 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-018788","json":"https://secwatch.observer/filing/0000950170-23-018788.json","markdown":"https://secwatch.observer/filing/0000950170-23-018788.md","text":"https://secwatch.observer/filing/0000950170-23-018788.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023018788/0000950170-23-018788-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023018788/enta-20230508.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T12:18:34.450384+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c3101543f0366c2f667432675b19eaf7aee289b","claim":"ENANTA PHARMACEUTICALS INC reported fiscal second quarter ended March 31, 2023 results: revenue $17.8 million, net income net loss of $37.7 million, or a loss of $1.79 per diluted common share, EPS a loss of $1.79 per diluted common share.","evidence_excerpt":"Total revenue for the three months ended March 31, 2023 was $17.8 million and consisted of royalty revenue from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET® (glecaprevir/pibrentasvir), compared to $18.7 million for the three months ended March 31, 2022. Research and development expenses totaled $43.5 million for the three months ended March 31, 2023, compared to $42.1 million for the three months ended March 31, 2022. The increase was primarily due to the timing of clinical trial expenses in our virology programs. General and administrative expenses totaled $13.8 million for the three months ended March 31, 2023, compared to $10.5 million for the three months ended March 31, 2022. The increase was due to increased stock-related compensation expense and legal fees associated with our patent infringement suit against Pfizer. Net loss for the three months ended March 31, 2023 was $37.7 million, or a loss of $1.79 per diluted common share, compared to a","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1177648/000095017023018788/0000950170-23-018788-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal second quarter ended March 31, 2023"},{"label":"Revenue","value":"$17.8 million"},{"label":"Net income","value":"net loss of $37.7 million, or a loss of $1.79 per diluted common share"},{"label":"EPS","value":"a loss of $1.79 per diluted common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}